SCHEDULE: Baker Bros. Advisors Discloses 6.9% Stake in Edgewise

Baker Bros. Advisors and its affiliates have disclosed a 6.9% beneficial ownership stake in Edgewise Therapeutics, Inc., holding over 7.3 million shares.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker collectively hold 7,305,940 shares of Edgewise Therapeutics, Inc. Common Stock.
• This ownership represents 6.9% of the outstanding Common Stock.
• The shares are held through Baker Brothers Life Sciences, L.P. (6,762,577 shares, representing 6.4% of outstanding Common Stock) and 667, L.P. (543,363 shares, representing 0.5% of outstanding Common Stock).
• The percentage of beneficial ownership is calculated based on 105,200,221 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Form 10-Q filed on May 8, 2025.
• This filing is an Amendment No. 1 to a previously filed Schedule 13G.
• The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a neutral, factual disclosure of beneficial ownership. However, the identity of the investor (Baker Bros. Advisors) and the size of the stake (6.9%) could be perceived positively by the market, indicating institutional confidence.

Positives

• A significant investment by Baker Bros. Advisors, a prominent institutional investor group specializing in biotechnology, indicates strong confidence in Edgewise Therapeutics, Inc.
• The filing states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive, long-term investment perspective.

Future Outlook

NA

Industry Context

Baker Bros. Advisors is a highly specialized and influential investment firm with a strong focus on the biotechnology and life sciences sectors. Their investment in Edgewise Therapeutics, a company operating within this domain, aligns perfectly with their established investment strategy and portfolio composition.

Comparison to Industry Standards

• Baker Bros. Advisors is recognized as a leading institutional investor in the biotech industry, often taking substantial positions in companies with promising pipelines or technologies. Their 6.9% stake in Edgewise Therapeutics is a significant position, comparable to other major biotech-focused funds' strategic investments in emerging or clinical-stage companies.
• The investment signals a level of due diligence and confidence that is often sought after by other investors in the biotech space, similar to how investments by funds like Orbimed or RA Capital Management are perceived.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Baker Bros. Advisors could instill confidence and potentially attract other investors, positively impacting share price.
• Management: May view the investment as a vote of confidence in their strategy and pipeline.

Key Dates

Recommendation

The Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Baker Bros. Advisors, a highly respected institutional investor in the biotechnology sector. While the filing itself does not contain financial performance metrics or strategic updates, the fact that a prominent fund like Baker Bros. holds a 6.9% stake in Edgewise Therapeutics is a positive signal. This indicates a significant vote of confidence from an investor known for deep industry expertise and long-term investment horizons in promising biotech companies. For existing investors, this reinforces the investment thesis, suggesting a 'hold' position to observe future developments. For potential investors, it warrants further due diligence into Edgewise Therapeutics' pipeline and fundamentals, as the institutional backing is a strong qualitative factor.

Keywords

Edgewise Therapeutics, Baker Bros. Advisors, Institutional Investment, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Life Sciences